Noradrenaline dopamine-reuptake inhibitors

Author(s):  
Peter Silverstone
Keyword(s):  
1995 ◽  
Vol 3 (3) ◽  
pp. 219-231 ◽  
Author(s):  
John R. Glowa ◽  
Francis H. E. Wojnicki ◽  
Dorota Matecka ◽  
John D. Bacher ◽  
Robert S. Mansbach ◽  
...  
Keyword(s):  

2018 ◽  
Author(s):  
Vikas Navratna ◽  
Dilip K. Tosh ◽  
Kenneth A. Jacobson ◽  
Eric Gouaux

AbstractThe human dopamine transporter(hDAT) plays a major role in dopamine homeostasis and regulation of neurotransmission by clearing dopamine from the extracellular space using secondary active transport. Dopamine is an essential monoamine chemical messenger that regulates reward seeking behavior, motor control, hormonal release, and emotional response in humans. Psychostimulants such as cocaine primarily target the central binding site of hDAT and lock the transporter in an outward-facing conformation, thereby inhibiting dopamine reuptake. The inhibition of dopamine reuptake leads to accumulation of dopamine in the synapse causing heightened signaling. In addition, hDAT is implicated in various neurological disorders and disease-associated neurodegeneration. Despite its significance, the molecular architecture of hDAT and its various conformational states are poorly understood. Instability of hDAT in detergent micelles has been a limiting factor in its successful biochemical, biophysical, and structural characterization. To overcome this hurdle, first we identified ligands that stabilize hDAT in detergent micelles. Then, we screened ∼200 single residue mutants of hDAT using high-throughput scintillation proximity assay, and identified a thermostable variant(I248Y). Here we report a robust strategy to overexpress and successfully purify a thermostable variant of hDAT in an inhibitor and allosteric ligand bound conformation.


PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e58251 ◽  
Author(s):  
Jackson J. Cone ◽  
Elena H. Chartoff ◽  
David N. Potter ◽  
Stephanie R. Ebner ◽  
Mitchell F. Roitman

2018 ◽  
Vol 75 (23) ◽  
pp. 4357-4370 ◽  
Author(s):  
Abla Benleulmi-Chaachoua ◽  
Alan Hegron ◽  
Marine Le Boulch ◽  
Angeliki Karamitri ◽  
Marta Wierzbicka ◽  
...  

2006 ◽  
Vol 27 (5) ◽  
pp. 609-620 ◽  
Author(s):  
Anna Fiorentino ◽  
Deepangi Pandit ◽  
Kathleen M. Gilbert ◽  
Milind Misra ◽  
Rose Dios ◽  
...  

2011 ◽  
Vol 7 (6) ◽  
pp. 753-761 ◽  
Author(s):  
Hongxia Zhou ◽  
Cao Huang ◽  
Jianbin Tong ◽  
Weimin C Hong ◽  
Yong-Jian Liu ◽  
...  

Molecules ◽  
2019 ◽  
Vol 24 (23) ◽  
pp. 4218 ◽  
Author(s):  
Koprdova ◽  
Csatlosova ◽  
Durisova ◽  
Bogi ◽  
Majekova ◽  
...  

SMe1EC2M3 is a pyridoindole derivative related to the neuroleptic drug carbidine. Based on the structural similarities of SMe1EC2M3 and known serotonin (5-HT), norepinephrine, and dopamine reuptake inhibitors, we hypothesized that this compound may also have triple reuptake inhibition efficacy and an antidepressant-like effect. PreADMET and Dragon software was used for in silico prediction of pharmacokinetics and pharmacodynamics of SMe1EC2M3. Forced swim test was used to evaluate its antidepressant-like effects. Extracellular in vivo electrophysiology was used to assess 5-HT, norepinephrine, and dopamine reuptake inhibition efficacy of SMe1EC2M3. PreADMET predicted reasonable intestinal absorption, plasma protein binding, and blood-brain permeability for SMe1EC2M3. Dragon forecasted its efficiency as an antidepressant. Using behavioral measurements, it was found that SMe1EC2M3 decreased immobility time and increase swimming time during the forced swim test (FST). Electrophysiological investigations showed that SMe1EC2M3 dose-dependently suppressed the excitability of 5-HT neurons of the dorsal raphe nucleus (DRN), norepinephrine neurons of the locus coeruleus (LC), and dopamine neurons of the ventral tegmental area (VTA). The SMe1EC2M3-induced suppression of 5-HT, norepinephrine, and dopamine neurons was reversed by the antagonists of serotonin-1A (5-HT1A; WAY100135), α-2 adrenergic (α2, yohimbine), and dopamine-2 receptors (D2, haloperidol), respectively. We conclude that SMe1EC2M3 is prospective triple 5-HT, norepinephrine, and dopamine reuptake inhibitor with antidepressant-like properties, however future studies should be performed to complete the pharmacological profiling of this compound.


Sign in / Sign up

Export Citation Format

Share Document